Respicardia
OverviewSuggest Edit
Respicardia is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time.
| Type | Private | |
| Founded | 2006 | |
| HQ | Hopkins, MN, US | Map |
| Website | respicardia.com |
Latest Updates
| Employees (est.) (Jul 2021) | 78 | (-2%) |
| Cybersecurity rating | C | More |
Key People/Management at Respicardia
B. Kristine Johnson
Director
Peter Sommerness
President and CEO, Director
Tim Hauch
Chief Financial Officer
Kirk Nielsen
Director
Robin Germany
Chief Medical Officer
Jonathan A. Rennert
Director
Respicardia Office Locations
Respicardia has an office in Hopkins
Hopkins, MN, US (HQ)
12400 Whitewater Dr #150
Respicardia Financials and Metrics
Summary Metrics
Founding Date | 2006 |
Respicardia total Funding | $149.1 m |
Respicardia latest funding size | $58.5 m |
Time since last funding | 4 years ago |
Respicardia investors | Polaris Partners, Versant Ventures, Three Arch Partners, Accuitive Medical Ventures, Affinity Capital Management, RK Ventures Group, Sorin Group, Polaris Venture Capital, Abbott, ZOLL Medical Corporation |
Respicardia's latest funding round in December 2017 was reported to be $58.5 m. In total, Respicardia has raised $149.1 m
Respicardia Cybersecurity Score
Respicardia Online and Social Media Presence
Respicardia's Trends
Respicardia News and Updates
January 07, 2021
Respicardia Announces Highmark Coverage for the remedē® System in Patients with Central Sleep Apnea
MINNETONKA, Minn., Jan. 7, 2021 /PRNewswire/ -- Respicardia, Inc., the manufacturer of the only FDA-approved active implantable system for the treatment of central sleep apnea (CSA), announced today that Highmark Blue Cross Blue Shield and its affiliates will provide coverage for the...
August 06, 2018
CMS Grants New Technology Add-on Payment to the remedē® System for the Treatment of Central Sleep Apnea
MINNETONKA, Minn., Aug. 6, 2018 /PRNewswire/ -- Respicardia, Inc., a medical technology company developing innovative therapies that improve cardiovascular health, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved a New Technology Add-On Payment (NTAP) ...
Respicardia Blogs
July 09, 2021
MIKE’S SLEEP APNEA DISRUPTED HIS SLEEP AND LIFESTYLE UNTIL HE FOUND A THERAPY OFFERED AT HIS LOCAL VA HOSPITAL
Mike shares how the daily disruptions caused by his undiagnosed CSA led him to a sleep study and an eventual treatment.
The post MIKE’S SLEEP APNEA DISRUPTED HIS SLEEP AND LIFESTYLE UNTIL HE FOUND A THERAPY OFFERED AT HIS LOCAL VA HOSPITAL appeared first on Respicardia.
May 20, 2021
THE PREVALENCE OF CENTRAL SLEEP APNEA IN A COMMUNITY BASED STUDY
A large community-based study was conducted to test the prevalence of a particular form of central sleep apnea (CSA): CSA and cheyne-stokes respiration (CSR) using current clinical definitions. The study was unique in that it was conducted in a community setting instead of a controlled clinical envi…
May 17, 2021
ZOLL Announces Five-Year Study Confirming Safety, Efficacy and Beneficial Effects of Long-Term Transvenous Phrenic Nerve Stimulation (the remedē System)
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the peer-reviewed journal Nature and Science of Sleep has published five-year results from the remedē System Post Approval Study.
The post <a href="https://www.zoll.com/news-releases/2021/05/17/zoll-announces-five-year-study-confirming-safety-efficacy-beneficial-effects-long-term-transvenous…
April 16, 2021
UNDERSTANDING COMMERCIAL AND MEDICARE ADVANTAGE INSURANCE COVERAGE FOR THE remedē® SYSTEM
For people with central sleep apnea, understanding exactly which treatment options are covered under your insurance policy can be time- consuming. Every insurance plan is different, but this blog is designed to help those of you with Medicare Advantage or Commercial insurance understand the prior au…
April 12, 2021
ZOLL Medical Corporation acquires Respicardia, Inc.
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has acquired Respicardia, Inc., a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA).
The post ZOL…
April 07, 2021
CENTRAL SLEEP APNEA (CSA) AND EXCESSIVE DAYTIME SLEEPINESS
Excessive daytime sleepiness (EDS) is a potential symptom of sleep apnea. This blog will focus specifically on how daytime sleepiness impacts people with central sleep apnea (CSA).
The post CENTRAL SLEEP APNEA (CSA) AND EXCESSIVE DAYTIME SLEEPINESS appeared first on Respicardia.
Respicardia Frequently Asked Questions
When was Respicardia founded?
Respicardia was founded in 2006.
Who are Respicardia key executives?
Respicardia's key executives are B. Kristine Johnson, Peter Sommerness and Tim Hauch.
How many employees does Respicardia have?
Respicardia has 78 employees.
Who are Respicardia competitors?
Competitors of Respicardia include Tao Technologies, SinuSys and AdaptHealth.
Where is Respicardia headquarters?
Respicardia headquarters is located at 12400 Whitewater Dr #150, Hopkins.
Where are Respicardia offices?
Respicardia has an office in Hopkins.
How many offices does Respicardia have?
Respicardia has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies